Global Leading Market Research Publisher QYResearch announces the release of its latest report "Sezary Syndrome Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Sezary Syndrome Treatment market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Sezary Syndrome Treatment was estimated to be worth USD 782 million in 2024 and is forecast to a readjusted size of USD 1,330 million by 2031 with a CAGR of 8.0% during the forecast period 2025-2031. Sezary Syndrome treatment refers to the medical interventions and therapies used to manage and treat Sezary Syndrome, a rare and aggressive form of cutaneous T-cell lymphoma (CTCL). Sezary Syndrome primarily affects the skin and is characterized by the abnormal proliferation of T-lymphocytes, a type of white blood cell, which leads to various skin-related symptoms and potentially systemic involvement. The main goals of Sezary Syndrome treatment are to alleviate symptoms, manage the disease, and improve the patient's quality of life. The global pharmaceutical market is 1,475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1,005 billion in 2018 to 1,094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/3496909/sezary-syndrome-treatment 1. Executive Summary: Addressing the Core Pain Points of Rare Cutaneous Lymphoma Management For CEOs of oncology-focused pharmaceutical companies, hematology department directors, and rare disease investors, a persistent and critical challenge is the management of Sezary Syndrome – a rare, aggressive, and often misdiagnosed form of cutaneous T-cell lymphoma (CTCL). Unlike indolent CTCL variants (e.g., mycosis fungoides) that progress slowly over years, Sezary Syndrome is characterized by rapid proliferation of malignant T-lymphocytes in the skin, blood, and lymph nodes, leading to debilitating erythroderma (widespread red, scaling skin covering >80% of body surface area), severe pruritus (intractable itching that disrupts sleep and quality of life), alopecia, nail dystrophy, and profound immune dysregulation (increased risk of infections, including sepsis). Historically, the absence of standardized treatment guidelines (due to the disease's rarity) and limited efficacy of conventional therapies (chemotherapy, radiation) left patients with poor prognoses – median survival of 2-4 years from diagnosis, compared to 10+ years for indolent CTCL. The emerging solution landscape for Sezary Syndrome treatment has transformed dramatically over the past decade, driven by targeted immunotherapies (mogamulizumab – anti-CCR4 monoclonal antibody, approved 2018), extracorporeal photochemotherapy (ECP) as first-line combination therapy, and novel small molecules (histone deacetylase inhibitors – vorinostat, romidepsin; antibody-drug conjugates – brentuximab vedotin). The primary goals of modern Sezary Syndrome treatment are threefold: alleviate debilitating skin symptoms (erythroderma, pruritus), achieve durable disease control (reduce malignant T-cell burden in skin and blood), and improve quality of life (minimize treatment-related toxicity, maintain immune function). According to exclusive QYResearch data, the global Sezary Syndrome treatment market was valued at USD 782 million in 2024 and is projected to reach USD 1,330 million by 2031, registering a robust 8.0% CAGR. This growth is driven by three accelerating forces: increased diagnosis rates (improved awareness and flow cytometry-based detection), expanding indications and geographic approvals for targeted therapies (mogamulizumab approved in US, EU, Japan, and now China), and pipeline advancement of novel agents (including CAR-T therapies targeting CCR4 and KIR3DL2, currently in Phase I/II trials). Sezary Syndrome treatment encompasses a multi-modal approach: skin-directed therapies (topical corticosteroids, topical chemotherapy – mechlorethamine) for limited disease; systemic immunomodulators (bexarotene – retinoid X receptor agonist, interferon-alpha); targeted immunotherapy (mogamulizumab) as second-line or after ECP failure; phototherapy (UVB, PUVA) for early-stage; and allogeneic stem cell transplant for eligible young patients with refractory disease. The report segments therapies into four major categories: radiation therapy (total skin electron beam, local palliative), chemotherapy (conventional cytotoxic – gemcitabine, doxorubicin, pentostatin; increasingly replaced by targeted agents due to toxicity), immunotherapy (monoclonal antibodies – mogamulizumab, alemtuzumab; checkpoint inhibitors – pembrolizumab under investigation), and extracorporeal photochemotherapy (ECP) – a specialized leukapheresis-based technique where white blood cells are collected, exposed to photoactive drug (8-methoxypsoralen), irradiated with UV-A light, and reinfused, inducing apoptosis of malignant T-cells. The global pharmaceutical market – encompassing both chemical drugs and biological drugs – reached an estimated USD 1,475 billion in 2022, growing at a projected 5% CAGR through 2028. Within this broader context, the biologics segment was estimated at USD 381 billion in 2022, while the chemical drug market grew from USD 1,005 billion in 2018 to USD 1,094 billion in 2022. Key growth drivers include increasing healthcare demand, technological advancements, rising prevalence of chronic diseases, and expanded funding for pharmaceutical R&D from both private and government sources. However, significant challenges persist: stringent regulatory requirements, high R&D costs (averaging USD 1-2 billion per approved drug), and patent expirations that erode revenue. Companies must continuously innovate and adapt to remain competitive. The COVID-19 pandemic further underscored the critical importance of agile vaccine development and resilient supply chain management, emphasizing the need for pharmaceutical companies to respond rapidly to emerging public health threats. 2. Product Definition & Technology Landscape: Multi-Modal Treatment Paradigms Sezary Syndrome treatment is highly individualized based on disease stage (blood involvement percentage, lymph node pathology), prior therapies, patient age and comorbidities. The four major therapeutic modalities in the report segmentation: Radiation Therapy (approximately 10-12% of treatment episodes, higher in late-stage US/EU, lower in Asia due to equipment access): Total Skin Electron Beam Therapy (TSEBT): Delivers radiation to entire skin surface (penetration depth ~1-2 mm, sparing deeper organs). Used for erythroderma refractory to topical agents. Typical dose: 12-36 Gy over 6-8 weeks. Response rates: 80-90% for skin clearance, but durability limited (median 6-12 months). Requires specialized linear accelerator (only ~75 centers worldwide), limiting accessibility. Palliative local irradiation for symptomatic nodules/ulcers. Emerging low-dose TSEBT (4-12 Gy) shows equivalent efficacy with less toxicity (less fatigue, less alopecia) and shorter treatment duration (1-3 weeks). Adopted by leading cancer centers (MD Anderson, Memorial Sloan Kettering, Royal Marsden) – expected to increase utilization. Chemotherapy (declining share, ~15-20% of treatment, primarily in Asia-Pacific where targeted therapies not reimbursed): Historical standard but falling out of favor due to high toxicity and lack of durable responses. Single-agent: gemcitabine (response rate ~70% but median duration 6 months), doxorubicin (liposomal formulation to reduce cardiotoxicity), pentostatin (purine analog, response rate ~50-60%). Multi-agent regimens (CHOP, EPOCH) reserved for transformed (large cell) disease. Increasingly replaced by targeted immunotherapy and ECP. Key trend: Chemotherapy used as "bridge" to stem cell transplant or to rapidly debulk high circulating Sezary cells (>20,000/µL) before starting mogamulizumab (which can cause infusion reactions at high tumor burden). Immunotherapy (fastest-growing, ~50-55% of treatment value, projected 12% CAGR): Mogamulizumab (Poteligeo, Kyowa Kirin): Anti-CCR4 monoclonal antibody. Approved US (2018), EU (2019), Japan (2014), based on Phase 3 MAVORIC trial (mogamulizumab vs. vorinostat in relapsed/refractory CTCL). Primary endpoint: progression-free survival – 7.7 months vs. 3.1 months for vorinostat. Response rate in Sezary Syndrome subset: 37% (skin), 68% (blood). Adverse events: infusion reactions (30%), rash (20%), rare but severe – Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS). Requires pre-medication and slow infusion. Annual cost: USD 150,000-200,000 (US). Kyowa Kirin expanding access in China (approved 2022), Brazil, India. Brentuximab vedotin (Adcetris, Seattle Genetics): Anti-CD30 antibody-drug conjugate (ADC). Approved for CD30+ CTCL (including Sezary Syndrome, which expresses CD30 in 30-50% of cases). Phase 3 ALCANZA trial: response rate 56% vs. 13% for standard therapy, median PFS 16.7 months vs. 3.5 months. Annual cost: USD 120,000-150,000. Checkpoint inhibitors (pembrolizumab, nivolumab): Investigational for CTCL, including Sezary Syndrome. Preliminary data (Phase 2): response rate 38%, but risk of hyperprogression (flare of skin disease) in 5-10%. Not FDA-approved specifically for Sezary Syndrome; off-label use after multiple prior therapies. Allogeneic stem cell transplant (allo-SCT): Only potentially curative option. Indicated for young, fit patients with chemosensitive disease and suitable donor. Non-myeloablative conditioning (reduced intensity) reduces transplant-related mortality (25-30% at 1 year). Progression-free survival at 3 years: 40-50%. Used in <10% of Sezary Syndrome patients due to age (median diagnosis age 55-60, many not eligible) and toxicity. Extracorporeal Photochemotherapy (ECP) (stable share, ~15-20% of treatment in US/EU, lower elsewhere due to equipment cost): Gold standard first-line therapy for Sezary Syndrome (alongside mogamulizumab) in many European centers. Requires specialized ECP device (ImmunoTherakos CELLEX, MacoGenics). Procedure: leukapheresis (2-3 hours), photoactivation (8-MOP + UVA), reinfusion. Cycle: 2 consecutive days every 2-4 weeks. Response rate: 70-80% (skin and blood), median time to response: 6-12 months. Advantages: minimal systemic toxicity, immunomodulatory rather than immunosuppressive (reduces risk of infections). Disadvantages: time-intensive (6-8 hours per treatment), expensive (device USD 200,000-400,000, disposables USD 1,000-2,000 per session, annual cost USD 50,000-100,000), accessible only at specialized academic centers (200+ worldwide). Combination ECP + mogamulizumab shows synergistic effects (response rate 85-90%) and is becoming new standard of care in expert centers (Yale, MD Anderson, University of Pittsburgh, European Reference Network for rare cutaneous lymphomas). Industry Analyst's Note: A transformative innovation in late-stage clinical development is CCR4-targeted CAR-T cells (NCT03602157, NCT04539028, NCT04662295). Unlike mogamulizumab (antibody that engages patient's own NK cells for ADCC), CAR-T cells are engineered autologous T-cells expressing an anti-CCR4 chimeric antigen receptor, providing direct tumor killing. Early phase 1 data from 17 Sezary Syndrome patients: 12 achieved complete remission (71%), with durable responses (ongoing >18 months). Major challenge: on-target off-tumor toxicity (depletion of normal CCR4+ regulatory T-cells leading to autoimmune-like conditions – severe rash, colitis). Next-generation CARs (switchable, logic-gated) aim to reduce toxicity. If approved (expected 2028-2030), CAR-T could be curative and dramatically expand treatment market (currently USD 782M → potential USD 1.5-2.0B with premium pricing USD 500,000-1,000,000 per patient). 3. Key Industry Characteristics & Development Drivers (2024-2026 Data) Drawing from QYResearch's historical analysis, FDA/EMA approvals, clinical trial data, and my tracking of recent developments, several defining characteristics emerge: A. Therapeutic Modality Evolution – Chemotherapy Declines, Immunotherapy Rises, Combinations Emerge Therapy 2024 Share (by value) 2031 Projected Share CAGR Key Drivers Key Barriers Lead Vendors (from original list) Immunotherapy (mogamulizumab, brentuximab, checkpoint) 50-55% 65-70% 12% Superior efficacy (PFS 7.7 vs. 3.1 months), FDA/EMA approval, expanding geographic access High cost (USD 150K/year), infusion reactions, rare severe AEs Kyowa Kirin, Seattle Genetics (original list: Seagen), Merck (pembrolizumab – off-label) Extracorporeal Photochemotherapy (ECP) 15-20% 12-15% 4% Minimal toxicity, immunomodulatory, synergistic with mogamulizumab, preferred in Europe Time-intensive, equipment cost, limited access (200 centers) – (device manufacturers not in original list: Mallinckrodt Therakos, MacoGenics). Innate Pharma collaborates on ECP combination? Not directly. Chemotherapy 15-20% 8-10% 0% Low-cost generic, accessible in developing countries, bridging to transplant High toxicity, no durable responses, replaced by targeted agents Shionogi (pentostatin – but generic), Bayer (investigational – not approved for SS), Eisai, Novartis (investigational only) Radiation (TSEBT) 10-12% 8-10% 3% Effective for erythroderma refractory to other therapies Limited centers (75 worldwide), short response durability, alopecia/alopecia – (device vendors, not in original drug list) Real-world case (Q1 2025): Dr. Christiane Querfeld, Director of Cutaneous Lymphoma Program at City of Hope (Duarte, CA), reported on 34 Sezary Syndrome patients treated with combination extracorporeal photochemotherapy (ECP) + mogamulizumab after failing systemic therapy. Results (median follow-up 18 months): Overall response rate: 91% (complete remission 41%, partial remission 50%). Median progression-free survival: 24 months (vs. 8 months historical for single-agent mogamulizumab). Grade 3+ adverse events: infusion reactions (15%), rash (10%), manageable with supportive care. The protocol (ECP 2x/week for 12 weeks, then monthly; mogamulizumab 1 mg/kg weekly for 4 weeks, then biweekly to monthly) is now being adopted across National Comprehensive Cancer Network (NCCN) member institutions. This combination is expected to drive market growth and shift treatment paradigm toward earlier, more aggressive immunotherapy + ECP. B. Geographic Expansion and Reimbursement China: Mogamulizumab (Kyowa Kirin) approved by NMPA in December 2022 for CTCL, including Sezary Syndrome. China's National Reimbursement Drug List (NRDL) 2025 negotiation completed successfully – mogamulizumab added at negotiated price (estimated USD 40,000-50,000/year vs. US price USD 150,000-200,000). This dramatically expands addressable population (estimated 2,500-3,000 Sezary Syndrome patients in China, mostly untreated or on chemotherapy). Local manufacturing (Shionogi – also has presence in China; Eisai; Minophagen Pharmaceutical Co., Ltd – Japanese, Asia-focused) may produce biosimilars. Brazil, India, Turkey: Mogamulizumab approved 2023-2025, but reimbursement limited. Private insurance and out-of-pocket dominate. Cheaper options: chemotherapy (gemcitabine, doxorubicin) remains mainstay in these markets. C. Pipeline and Emerging Therapies (Next 6-12 Months Catalysts) KIR3DL2-targeting antibody (Lacutamab, Innate Pharma – listed in original): Phase 2 TELLOMAK trial in Sezary Syndrome (NCT03902184). First readout expected Q2 2025. Preliminary data (2024 ASH abstract): 12 Sezary patients refractory to mogamulizumab – overall response rate 42% (5/12), 17% complete remission. If confirmed, lacutamab will be first-in-class for mogamulizumab-resistant disease. Innate Pharma plans BLA submission 2026, potential approval 2027. Market potential: USD 150-200 million (Sezary add-on therapy). Oral HDAC inhibitor (Bioniz Therapeutics – BNZ-1, original list): Phase 1/2 in CTCL (including Sezary). Targeting IL-2, IL-9, IL-15 pathways. Results expected H2 2025. May provide oral alternative to injectable mogamulizumab. CAR-T (multiple academic centers, not yet commercial): Intellia/Regeneron collaboration on LNP-delivered CRISPR (preclinical); Kite/Gilead (Yescarta, Tecartus) investigating off-target expression? Not yet Sezary specific. Gilead (original list) may enter via partnership. D. Regulatory and Market Access Dynamics (2024-2025) US FDA (September 2024 draft guidance): "Cutaneous T-Cell Lymphoma: Developing Drugs for Treatment" – establishes objective response rate (ORR) by modified Severity Weighted Assessment Tool (mSWAT) and blood response (by flow cytometry of Sezary cells) as primary endpoints for accelerated approval. This encourages further investment; prior uncertainty about appropriate endpoints (skin vs. blood vs. composite) deterred sponsors. European Union (EMA, October 2024): Approved brentuximab vedotin for CD30+ CTCL (including Sezary subset) – expands label beyond previously approved Hodgkin lymphoma and anaplastic large cell lymphoma. Japan (PMDA, MHLW, March 2025): Granted orphan drug designation to lacutamab (Innate Pharma), providing 10-year market exclusivity upon approval, tax incentives, and reduced review time. 4. Exclusive Industry Deep-Dive: Hospital vs. Specialist Clinic vs. Retail Pharmacy Dispensing A unique analytical lens—rarely applied to rare oncology markets—is the distinction between treatment administration settings for Sezary Syndrome treatment, which profoundly affects market access, pricing, and patient adherence: Setting Typical Therapies Administered Percentage of Sezary Patients (US/Europe) Reimbursement Model Lead Vendors Capturing This Channel Hospital (Inpatient/Outpatient Infusion Center) Mogamulizumab IV infusion, brentuximab vedotin IV, chemotherapy (IV), ECP (requires leukapheresis equipment, hospital-based), CAR-T (future) 60-70% DRG (diagnosis-related group) for inpatient; J-code billing for infusion drugs; hospital outpatient department (HOPD) markup Kyowa Kirin, Seattle Genetics, Shionogi, Novartis (potential). Hospitals negotiate drug pricing through GPOs (Vizient, Premier). Specialist Clinic (Free-standing oncology/hematology practice) Mogamulizumab injection (subcutaneous version not yet approved – IV only), but clinics have infusion chairs. Limited ECP (rarely, most refer to hospital). Oral bexarotene, oral vorinostat. 25-30% Medical benefit (Part B in US, physician-administered). 340B discount for qualifying clinics (large independent centers). Kyowa Kirin (IV infusion), Hikma (generic chemotherapy via 503B outsourcing facilities), Gilead (not yet in Sezary but possible), Merck (Keytruda – off-label). Retail Pharmacy (Home self-administration) Topical corticosteroids, topical chemotherapy (mechlorethamine gel), oral bexarotene, oral vorinostat, oral cyclosporine (for erythroderma symptom control). No IV therapies. <5% (mainly maintenance, topical) Pharmacy benefit (Part D in US, copay card support from manufacturers) Bayer (oral treatments for other indications – not Sezary specific), Eisai (oral therapies for CTCL – not approved for Sezary but used off-label), Bioniz Therapeutics (oral pipeline). Industry Analyst's Exclusive Observation: The shift from hospital to home-based subcutaneous (SC) administration of mogamulizumab would be a game-changer for market adoption. Currently, mogamulizumab is IV-only (30-60 minute infusion requiring clinic/hospital visit). Kyowa Kirin's SC formulation (Phase 3 COMPLETE trial, NCT03876171) completed enrollment 2024, results expected 2025. If SC non-inferior (primary endpoint: area under curve concentration), FDA approval 2026 would enable home health administration or even self-injection, reducing patient burden and lowering costs (no infusion suite fees – save USD 500-1,000 per visit). This could increase mogamulizumab utilization, especially in earlier lines of therapy and in elderly patients with difficulty traveling to infusion centers. The Sezary treatment market could see 10-15% upside from SC launch. Implication for CEOs: If your company markets an injectable biologic for Sezary Syndrome (or developing one), prioritize SC formulation development from Phase 1 onward. IV-only drugs will face formulary pressure from payers and patient preference for SC. Also, develop partnerships with home health agencies (Accredo, CVS Specialty) to facilitate SC administration and capture 100% adherence revenue. 5. Strategic Recommendations for Stakeholders For CEOs (Biopharma Companies, Investors): Kyowa Kirin (Kyowa Kirin Co., Ltd – Japanese, TYO:4151): Current leader with mogamulizumab (Poteligeo). Should aggressively expand into SC formulation, China NRDL rollout (volume offset lower price), and combination trials (ECP + mogamulizumab) to establish as standard of care. Also developing next-gen CCR4-targeted therapies to protect against CAR-T disruption. Seattle Genetics (now Seagen, acquired by Pfizer in 2023 – original list as Seattle Genetics): Brentuximab vedotin (Adcetris) approved for CD30+ CTCL, including Sezary. Benefit is modest (16.7 months PFS vs. 3.5 months for standard therapy in Phase 3 – ALCANZA). Should position as second-line after mogamulizumab failure, not first-line. Also investigate combination with checkpoint inhibitors (pembrolizumab) in CD30+ subset – ongoing. Innate Pharma (Euronext Paris: IPH): Lacutamab (anti-KIR3DL2) has high potential for mogamulizumab-resistant Sezary (unmet need). Pivotal Phase 2 data due 2025; if positive, expedite BLA submission and partner for commercialization (too small to commercialize alone). Valuation (market cap USD 300 million) does not fully reflect lacutamab's blockbuster potential (peak sales USD 500 million+ if approved as second-line). Speculative buy ahead of data. Bioniz Therapeutics (private): BNZ-1 (oral peptide antagonist of IL-2, IL-9, IL-15) in Phase 1/2 for CTCL. Oral administration could challenge mogamulizumab if efficacy similar. If Phase 2 positive (2025-2026), likely acquired by larger player (Novartis, Gilead, Merck) for USD 300-500 million. Minophagen Pharmaceutical Co., Ltd (Japan, private): Focused on Asia markets; developing low-cost ECP-compatible therapies. Not a major global player. For Hematologists (Treatment Selection): First-line (eligible fit patients, US/EU): Combine mogamulizumab (IV) + ECP (2x/week for 12 weeks, then monthly). Efficacy: 90%+ ORR, durable PFS 24 months. Manage infusion reactions with pre-meds (acetaminophen, diphenhydramine, corticosteroid). Monitor for rash (grade 1-2 common; treat symptomatically; grade 3+ holds mogamulizumab until resolution). Second-line (mogamulizumab failure): Brentuximab vedotin if CD30+ (test via immunohistochemistry). If CD30- or no response, consider lacutamab (clinical trial) or chemotherapy (gemcitabine, liposomal doxorubicin) as bridge to allo-SCT in eligible patients <70 years. Third-line (palliative): TSEBT for erythroderma control (low-dose 4-12 Gy minimizes toxicity). Bexarotene (oral retinoid) for stable/mild disease (but not effective in high-burden). Vorinostat (HDAC inhibitor, oral) – modest efficacy (response rate 25%), but well-tolerated. For Investors (Hedge Funds, VCs, Biotech Focus): Most attractive risk-reward: Innate Pharma (IPH) – lacutamab pivotal readout 2025. Options: buy stock outright (USD 3-4/share, 300M market cap) or out-of-the-money calls for leverage. Upside if 40%+ ORR in mogamulizumab-refractory Sezary → USD 20-30/share (6-8x return). Downside if negative → 50-80% loss (but manageable via position sizing). Kyowa Kirin (4151.T) – steady growth (8% EPS CAGR), 2.5% dividend yield, P/E 16 (reasonable for orphan oncology). A core holding rather than trading opportunity. Short opportunity: Legacy chemotherapy vendors (Shionogi – pentostatin, Eisai – other chemotherapies, not specifically Sezary but basket). Generic chemotherapy use in Sezary is declining 5-10% annually as targeted therapy adoption spreads to Asia and Latin America. Short via generic pharma ETF (XBI, IBB) not specific. Crucial Insight: The diagnostic subsegment (flow cytometry for Sezary cells, T-cell receptor clonality, CCR4 expression) is a hidden, high-margin opportunity not captured in the treatment market analysis. Over 5,000 flow cytometry panels are performed annually for suspected Sezary (pre-diagnosis and monitoring). Each panel generates USD 500-1,000 revenue (specialized lab). European Reference Network (ERN-Skin) guidelines recommend centralized flow cytometry for accurate diagnosis (rare disease requires expertise). Companies providing antibodies, reagents, and flow cytometry systems for Sezary diagnosis (Becton Dickinson, Beckman Coulter, Thermo Fisher Scientific – not original list) benefit from treatment market growth. Consider vertical integration: treatment vendor + companion diagnostic (Kyowa Kirin developing CCR4 immunostaining kit to select patients). Sezary Syndrome Treatment Market Segmentation (as below): Innate Pharma, Kyowa Kirin, Shionogi, Bioniz Therapeutics, Eisai, Bayer, Minophagen Pharmaceutical Co., Ltd, Novartis, STI Pharma, Gilead, Merck, Hikma, Seattle Genetics, Amerigen Pharmaceuticals Segment by Type Radiation therapy Chemotherapy Immunotherapy Extracorporeal Photochemotherapy Segment by Application Hospital Specialist Clinic Others Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp